Skip to main content

Table 1 Body weight and glycaemic, insulinaemic and lipidic profile in the rats under study at the initial and final times

From: Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties

Time

Initial time (20 wks old rats)

Final time (26 wks old rats)

Groups

Control

Diabetic

Control

Diabetic

Parameters

Vehicle (n = 10)

Vehicle (n = 15)

Vehicle (n = 5)

Vehicle (n = 5)

Sitagliptin (n = 5)

BW (g)

406.70 ± 6.83

388.10 ± 8.87

445.70 ± 8.16

354.40 ± 8.85aaa

380.00 ± 14.46

Glucose (mg/dl)

131.80 ± 1.20

512.00 ± 4.53aaa

133.40 ± 2.16

623.60 ± 7.30bb

520.44 ± 3.31ccc

HbA1c (%)

3.66 ± 0.15

9.96 ± 0.86aaa

3.76 ± 0.26

10.68 ± 0.75

8.68 ± 0.37ccc

Insulin (mU/ml)

14.82 ± 3.90

11.62 ± 1.15aaa

15.13 ± 3.34

7.16 ± 1.14bbb

11.19 ± 1.73ccc

HOMA-Beta (%)

77.70 ± 2.28

9.33 ± 0.83aaa

77.52 ± 1.10

4.60 ± 0.16bbb

8.82 ± 0.32ccc

TGs (mg/dl)

111.60 ± 8.33

366.00 ± 5.92aaa

158.40 ± 6.80

409.80 ± 8.04bb

255.60 ± 3.70ccc

  1. Values are means ± SEM of n rats. Comparisons between groups: aaa = p < 0.001 between diabetic versus control groups (20 or 26 weeks); bb and bbb = p < 0.01 and p < 0.001, respectively, within the diabetic group (26 versus 20 weeks); ccc = p < 0.001 between diabetic sitagliptin-treated versus diabetic untreated groups (at 26 weeks).
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us